Type III interferon (IFN-λ) antagonizes the antiviral activity of interferon-α in vitro

Journal of Biological Regulators and Homeostatic Agents

Volumn 27, Issue 4, 2013, Pages 1001-1009

  Bordi, L ^a   Lalle, E ^a   Lapa, D ^a   Caglioti, C ^a   Quartu, S ^a   Capobianchi, Maria Rosaria ^a   Castilletti, C ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antagonism; Antiviral activity; Combination index; IFN ; IFN ; Interferon stimulated genes

Indexed keywords

'INTRON'; INTERFERON; INTERFERON 12; INTERLEUKIN 29; MESSENGER RNA; RECOMBINANT ALPHA INTERFERON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL LEVEL; CHIKUNGUNYA ALPHAVIRUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENCEPHALITIS VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; INTRACELLULAR SIGNALING; NONHUMAN; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; VERO CELL; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; WEST NILE FLAVIVIRUS;

2',5'-OLIGOADENYLATE SYNTHETASE; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; ENCEPHALOMYOCARDITIS VIRUS; HUMANS; INTERFERON-ALPHA; INTERFERONS; INTERLEUKINS; MYXOVIRUS RESISTANCE PROTEINS; VERO CELLS; VIRUS REPLICATION;

EID: 84893261479     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202:8-32. (Pubitemid 39576902)
2. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75:163-189. (Pubitemid 38174573)
3. Thomson A: The cytokine handbook, 3rd ed. San Diego, CA, Academic Press; 1998.
4. Ank N, West H, Paludan SR. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res. 2006; 26:373-9.
5. Kotenko SV, Gallagher G, Baurin VV, et al. IFN lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69-77. (Pubitemid 36109115)
6. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFNlambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4:e1000017.
7. Cheng M, Si Y, Yang Y, et al. Recombinant human interleukin 28B: anti-HCV potency, receptor usage and restricted cell-type responsiveness. J Antimicrob Chemother 2012; 67:1080-7.
8. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 2010; 4:237-51.
9. Scagnolari C, Caputo B, Trombetti S, et al. Usutu virus growth in human cell lines: induction of and sensitivity to type I and III interferons. J Gen Virol 2013; 94:789-95.
10. Stoltz M, Klingström J. Alpha/beta interferon (IFN-alpha/beta)- independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection. J Virol 2010; 84:9140-8.
11. Martens S, Howard J. The interferon-inducible GTPases. Annu Rev Cell Dev Biol 2006; 22:559-89.
12. Haller O, Staeheli P, Kochs G. Interferon-induced Mx proteins in antiviral host defense. Biochimie 2007; 89:812-8. (Pubitemid 47001645)
13. Garcia MA, Gil J, Ventoso I, et al. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 2006; 70:1032-60. (Pubitemid 44958263)
14. Silverman RH. Viral encounters with OAS and RNase L during the IFN antiviral response. J Virol 2007; 81:12720-9.
15. Scagnolari C, Trombetti S, Alberelli A, et al. The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins. Intervirology 2007; 50:156-60.
16. Castilletti C, Bordi L, Lalle E, et al. Coordinate induction of IFN-alpha and -gamma by SARS-CoV also in the absence of virus replication. Virology 2005; 341:163-9 (Pubitemid 41356583)
17. Larkin J, Jin L, Farmen M, et al. Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system. J Interferon Cytokine Res 2003; 23:247-57. (Pubitemid 36606457)
18. Asper M, Sternsdorf T, Hass M, et al. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J Virol 2004; 78:3162-9. (Pubitemid 38314376)
19. Desloges N, Rahaus M, Wolff MH. Role of the protein kinase PKR in the inhibition of varicella-zoster virus replication by beta interferon and gamma interferon. J Gen Virol 2005; 86:1-6. (Pubitemid 40081144)
20. Sainz B Jr, LaMarca HL, Garry RF, Morris CA. Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma. Virol J 2005; 2:14.
21. Sainz B Jr, Halford WP. Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J Virol 2002; 76:11541-50. (Pubitemid 35231310)
22. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131:1887-98. (Pubitemid 44958521)
23. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80:4501-9.
24. François-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response. PLoS One 2011; 6:e22200.
25. Li MC, Wang HY, Wang HY, Li T, He SH. Liposome-mediated IL-28 and IL-29 expression in A549 cells and anti-viral effect of IL-28 and IL-29 on WISH cells. Acta Pharmacol Sin 2006; 27:453-9.
26. Bordi L, Carletti F, Castilletti C, et al. Presence of A226Vmutation in autocthonous and impeded italian Chikungunya virus strains. Clin Infect Dis 2008; 47:428-9. (Pubitemid 352009369)
27. Chou TC, Talalay YP. Quantitative analysis of dose-effect relationtips: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
28. Capobianchi MR, Lalle E, Martini F, Poccia F, D'Offizi G, Antonucci G, Abbate I, Dianzani F. Influence of GBV-C infection on the endogenous activation of the IFN system in HIV-1 co-infected patients. Cell Mol Biol 2006; 52: 3-8 (Pubitemid 43925156)
29. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41:1100-4.
30. Abbate I, Cappiello G, Rosati S, et al. Intra-hepatic messenger RNA levels for interferons and related genes in hepatitis C virus/HIV co-infected patients. AIDS. 2004;18:691-2. (Pubitemid 38393470)